| __timestamp | Amneal Pharmaceuticals, Inc. | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 26684000 |
| Thursday, January 1, 2015 | 109679000 | 29829000 |
| Friday, January 1, 2016 | 118757000 | 39578000 |
| Sunday, January 1, 2017 | 109046000 | 43277000 |
| Monday, January 1, 2018 | 230435000 | 48645000 |
| Tuesday, January 1, 2019 | 289598000 | 52934000 |
| Wednesday, January 1, 2020 | 326727000 | 61349000 |
| Friday, January 1, 2021 | 365504000 | 127125000 |
| Saturday, January 1, 2022 | 399700000 | 136106000 |
| Sunday, January 1, 2023 | 429675000 | 133175999 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical landscape, understanding spending patterns is crucial. Amneal Pharmaceuticals, Inc. and HUTCHMED (China) Limited offer a fascinating study in contrasts. Over the past decade, Amneal's Selling, General, and Administrative (SG&A) expenses have surged by over 400%, peaking at approximately $430 million in 2023. This reflects a strategic expansion and increased market penetration. In contrast, HUTCHMED's SG&A expenses, while also growing, have increased by about 400%, reaching around $133 million in the same year. This growth indicates a steady, albeit more conservative, approach to scaling operations. The data from 2014 to 2023 highlights the differing strategies of these two companies, with Amneal's aggressive expansion contrasting with HUTCHMED's more measured growth. As the pharmaceutical industry continues to evolve, these spending patterns offer insights into the strategic priorities and market positioning of these key players.
Breaking Down SG&A Expenses: Sanofi vs HUTCHMED (China) Limited
Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Amneal Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amneal Pharmaceuticals, Inc.
BeiGene, Ltd. vs HUTCHMED (China) Limited: SG&A Expense Trends
Comparing SG&A Expenses: Incyte Corporation vs HUTCHMED (China) Limited Trends and Insights
Selling, General, and Administrative Costs: Intra-Cellular Therapies, Inc. vs Amneal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bio-Techne Corporation vs Amneal Pharmaceuticals, Inc. Trends and Insights
Blueprint Medicines Corporation vs HUTCHMED (China) Limited: SG&A Expense Trends
Ionis Pharmaceuticals, Inc. and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Amneal Pharmaceuticals, Inc. vs Catalyst Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Dynavax Technologies Corporation